|
|
|
| November 1998, Volume 22, Number 10, Pages 989-994 |
| Table of contents Previous Abstract Next Article PDF |
 |
| Miscellaneous complications |
| Ovarian function after autologous bone marrow transplantation in childhood: high-dose busulfan is a major cause of ovarian failure |
|
| C Teinturier1,a, O Hartmann2, D Valteau-Couanet2, E Benhamou3 and P F Bougneres1 |
|
1Department of Pediatric Endocrinology, Hopital Saint-Vincent de Paul, Paris, France
2Department of Pediatric Oncology, Institut Gustave Roussy, Villejuif, France
3Department of Biostatistics, Institut Gustave Roussy, Villejuif, France
|
|
aCorrespondence: Dr C Teinturier, Service d'Endocrinologie Pediatrique, Hopital Saint-Vincent de Paul, 82, Avenue Denfert-Rochereau, 75014 Paris, France |
|
| Abstract |
| We studied pubertal status and ovarian function in 21 girls aged 11-21 years who had earlier received 1.2-13 years (median 7 years) high-dose chemotherapy and autologous BMT without TBI for malignant tumors. Ten of them were given busulfan (600 mg/m2) and melphalan (140 mg/m2) with or without cyclophosphamide (3.6 g/m2). Eleven others did not receive busulfan. Twelve girls (57%) had clinical and hormonal evidence of ovarian failure. Among nine others who had completed normal puberty, six had normal gonadotropin levels, one had elevated gonadotropin levels and two had gonadotropin levels at the upper limit of normal. The 10 girls who received busulfan all developed severe and persistent ovarian failure. High-dose busulfan is therefore a major cause of ovarian failure even when given in the prepubertal period. These findings emphasize the need for long-term endocrine follow-up of these patients in order to initiate estrogen replacement therapy. |
|
| Keywords |
| ovarian function; high-dose chemotherapy; bone marrow transplantation; busulfan; childhood |
|
|
|
|
| Received 18 February 1998; accepted 8 July 1998 |
|
| November 1998, Volume 22, Number 10, Pages 989-994 |
| Table of contents Previous Abstract Next Article PDF |
|
|
